Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2009

01-09-2009 | Review

Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?

Published in: Diabetologia | Issue 9/2009

Login to get access

Abstract

Prior to the development of type 2 diabetes, glucose levels increase into the prediabetic states of isolated impaired fasting glycaemia (i-IFG), isolated impaired glucose tolerance (i-IGT), or combined IFG/IGT. A better understanding of the aetiology and pathophysiology of the prediabetic states might give a basis for the development of individualised prevention and treatment strategies for type 2 diabetes. Several studies have examined mechanisms and potential aetiological factors leading to the development of the different prediabetic states. The pathophysiology of i-IFG seems to include the following key defects: reduced hepatic insulin sensitivity, stationary beta cell dysfunction and/or chronic low beta cell mass, altered glucagon-like peptide-1 secretion and inappropriately elevated glucagon secretion. Conversely, the prediabetic state i-IGT is characterised by reduced peripheral insulin sensitivity, near-normal hepatic insulin sensitivity, progressive loss of beta cell function, reduced secretion of glucose-dependent insulinotropic polypeptide and inappropriately elevated glucagon secretion. Individuals developing combined IFG/IGT exhibit severe defects in both peripheral and hepatic insulin sensitivity as well as a progressive loss of beta cell function. The aetiologies of i-IFG and i-IGT also seem to differ, with i-IFG being predominantly related to genetic factors, smoking and male sex, while i-IGT is predominantly related to physical inactivity, unhealthy diet and short stature. Since the transition from the prediabetic states to overt type 2 diabetes is characterised by a non-reversible vicious cycle that includes severe deleterious effects on glucose metabolism, there are good reasons to use the well-established aetiological and pathophysiological differences in i-IFG, i-IGT and IFG/IGT to design individualised preventive strategies.
Literature
1.
2.
Unger RH, Aguilar-Parada E, Müller WA, Eisentraut AM (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49:837–848PubMedCrossRef
3.
Dunning BE, Gerich JE (2007) The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28:253–283PubMedCrossRef
4.
Vilsbøll T, Knop FK, Krarup T et al (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab 88:4897–4903PubMedCrossRef
5.
Golay A, Swislocki AL, Chen YD, Reaven GM (1987) Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals. Metabolism 36:692–696PubMedCrossRef
6.
Stumvoll M, Chintalapudi U, Perriello G, Welle S, Gutierrez O, Gerich J (1995) Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest 96:2528–2533PubMedCrossRef
7.
Rasouli N, Kern P (2008) Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 93(11 Suppl 1):s64–s73PubMedCrossRef
8.
Basu A, Basu R, Shah P, Vella A, Rizza RA, Jensen MD (2001) Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 280:E1000–E1006PubMed
9.
Obici S, Zhang BB, Karkanias G, Rossetti L (2002) Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 8:1376–1382PubMedCrossRef
10.
DeFronzo RA (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58:773–795PubMedCrossRef
11.
O’Rahilly S, Hattersley A, Vaag A, Gray H (1994) Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy? Lancet 344:585–589PubMedCrossRef
12.
13.
Færch K, Vaag A, Holst J, Glümer C, Pedersen O, Borch-Johnsen K (2008) Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 51:853–861PubMedCrossRef
14.
Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA (2006) Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance—results from the veterans administration genetic epidemiology study. Diabetes 55:1430–1435PubMedCrossRef
15.
Weyer C, Bogardus C, Pratley RE (1999) Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48:2197–2203PubMedCrossRef
16.
Meyer C, Szoke E, Pimenta W et al (2006) Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 29:1909–1914PubMedCrossRef
17.
Tripathy D, Almgren P, Tuomi T, Groop L (2004) Contribution of insulin-stimulated glucose uptake and basal hepatic insulin sensitivity to surrogate measures of insulin sensitivity. Diabetes Care 27:2204–2210PubMedCrossRef
18.
Wasada T, Kuroki H, Katsumori K et al (2004) Who are more insulin resistant, people with IFG or people with IGT? Diabetologia 47:759–760CrossRef
19.
Færch K, Vaag A, Holst JJ, Hansen T, Jørgensen T, Borch-Johnsen K (2009) Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance—the Inter99 study. Diabetes Care 32:439–444PubMedCrossRef
20.
Abdul-Ghani MA, Sabbah M, Kher J, Minuchin O, Vardi P, Raz I (2006) Different contributions of insulin resistance and beta-cell dysfunction in overweight Israeli Arabs with IFG and IGT. Diabetes Metab Res Rev 22:126–130PubMedCrossRef
21.
Novoa FJ, Boronat M (2005) Saavedra P et al Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: The Telde study. Diabetes Care 28:2388–2393PubMedCrossRef
22.
DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed
23.
Man CD, Toffolo G, Basu R, Rizza RA, Cobelli C (2008) Use of labeled oral minimal model to measure hepatic insulin sensitivity. Am J Physiol Endocrinol Metab 295:E1152–E1159PubMedCrossRef
24.
Vaag A, Alford F, Henriksen FL, Christopher M, Beck-Nielsen H (1995) Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM. Diabetologia 38:326–336PubMedCrossRef
25.
Bock G, Chittilapilly E, Basu R et al (2007) Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: role of increased rates of gluconeogenesis. Diabetes 56:1703–1711PubMedCrossRef
26.
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102–110PubMedCrossRef
27.
Qiao Q (2005) Are insulin resistance, impaired fasting glucose and impaired glucose tolerance all equally strongly related to age? Diabet Med 22:1476–1481PubMedCrossRef
28.
Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005–2012PubMedCrossRef
29.
Chang-Chen K, Mullur R, Bernal-Mizrachi E (2008) Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord 9:329–343PubMedCrossRef
30.
Festa A, Williams K, D’Agostino R Jr, Wagenknecht LE, Haffner SM (2006) The natural course of beta cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55:1114–1120PubMedCrossRef
31.
Ahrén B, Pacini G (1997) Impaired adaptation of first-phase insulin secretion in postmenopausal women with glucose intolerance. Am J Physiol 273:E701–E707PubMed
32.
Laakso M, Zilinskaite J, Hansen T et al (2008) Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia 51:502–511PubMedCrossRef
33.
Gromada J, Franklin I, Wollheim CB (2007) Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 28:84–116PubMedCrossRef
34.
Ahrén B, Larsson H (2001) Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44:1998–2003PubMedCrossRef
35.
Abdul-Ghani MA, DeFronzo RA (2007) Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion. J Clin Endocrinol Metab 92:1778–1784PubMedCrossRef
36.
Mitrakou A, Kelley D, Mokan M et al (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22–29PubMed
37.
Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M (2005) Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Metabolism 54:1168–1173PubMedCrossRef
38.
Fritsche A, Stefan N, Hardt E, Häring H, Stumvoll M (2000) Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion. Diabetologia 43:852–858PubMedCrossRef
39.
Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340–1348PubMedCrossRef
40.
Ahrén B, Larsson H, Holst JJ (1997) Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur J Endocrinol 137:127–131PubMedCrossRef
41.
Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717–3723PubMedCrossRef
42.
Vollmer K, Holst JJ, Baller B et al (2008) Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 57:678–687PubMedCrossRef
43.
Abdul-Ghani MA, Molina-Carrion M, Jani R, Jenkinson C, DeFronzo R (2008) Adipocytes in subjects with impaired fasting glucose and impaired glucose tolerance are resistant to the anti-lipolytic effect of insulin. Acta Diabetol 45:147–150PubMedCrossRef
44.
Balkau B, Mhamdi L, Oppert JM et al (2008) Physical activity and insulin sensitivity: the RISC Study. Diabetes 57:2613–2618PubMedCrossRef
45.
Assah FK, Brage S, Ekelund U, Wareham NJ (2008) The association of intensity and overall level of physical activity energy expenditure with a marker of insulin resistance. Diabetologia 51:1399–1407PubMedCrossRef
46.
Færch K, Vaag A, Witte DR, Jørgensen T, Pedersen O, Borch-Johnsen K (2009) Predictors of future fasting and 2-hour post-OGTT plasma glucose levels in middle-aged men and women—the Inter99 study. Diabet Med 26:377–383PubMedCrossRef
47.
Healy GN, Dunstan DW, Shaw JE, Zimmet PZ, Owen N (2006) Beneficial associations of physical activity with 2-h but not fasting blood glucose in Australian adults. Diabetes Care 29:2598–2604PubMedCrossRef
48.
Assah FK, Ekelund U, Brage S, Mbanya JC, Wareham NJ (2009) free-living physical activity energy expenditure is strongly related to glucose intolerance in Cameroonian adults independently of obesity. Diabetes Care 32:367–369PubMedCrossRef
49.
Feskens EJ, Virtanen SM, Räsänen L et al (1995) Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 18:1104–1112PubMedCrossRef
50.
Van Dam RM, Stampfer M, Willett WC, Hu FB, Rimm EB (2002) Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care 25:417–424PubMedCrossRef
51.
Pereira MA, Jacobs DR, Pins JJ et al (2002) Effect of whole grains on insulin sensitivity in overweight hyperinsulinemic adults. Am J Clin Nutr 75:848–855PubMed
52.
Lau C, Glümer C, Toft U et al (2008) Identification and reproducibility of dietary patterns in a Danish cohort: the Inter99 study. Br J Nutr 99:1089–1098PubMedCrossRef
53.
Toft U, Kristoffersen LH, Lau C, Borch-Johnsen K, Jorgensen T (2006) The Dietary Quality Score: validation and association with cardiovascular risk factors: the Inter99 study. Eur J Clin Nutr 61:270–278PubMedCrossRef
54.
Lau C, Toft U, Tetens I et al (2009) Dietary patterns predict changes in two-hour post-oral glucose tolerance test plasma glucose concentrations in middle-aged adults. J Nutr 139:588–593PubMedCrossRef
55.
Mooy JM, Grootenhuis PA, de Vries H et al (1995) Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study. Diabetes Care 18:1270–1273PubMedCrossRef
56.
Smith U (1994) Carbohydrates, fat, and insulin action. Am J Clin Nutr 59(Suppl 3):686S–689SPubMed
57.
Feskens EJM, Kromhout D (1989) Cardiovascular risk factors and the 25-year incidence of diabetes mellitus in middle-aged men. The Zutphen Study. Am J Epidemiol 130:1101–1108PubMed
58.
Bamia C, Trichopoulou A, Lenas D, Trichopoulos D (2004) Tobacco smoking in relation to body fat mass and distribution in a general population sample. Int J Obes Relat Metab Disord 28:1091–1096PubMedCrossRef
59.
Song F, Jia W, Yao Y et al (2007) Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed type 2 diabetes. Clin Sci 112:599–606PubMedCrossRef
60.
Kong C, Nimmo L, Elatrozy T et al (2001) Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes. Atherosclerosis 156:373–378PubMedCrossRef
61.
Lyssenko V (2008) The transcription factor 7-like 2 gene and increased risk of type 2 diabetes: an update. Curr Opin Clin Nutr Metab Care 11:385–392PubMedCrossRef
62.
Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 117:2155–2163PubMedCrossRef
63.
Wegner L, Hussain MS, Pilgaard K et al (2008) Impact of TCF7L2 rs7903146 on insulin secretion and action in young and elderly Danish twins. J Clin Endocrinol Metab 93:4013–4019PubMedCrossRef
64.
Sparsø T, Bonnefond A, Andersson E et al (2009) G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release. Diabetes 58:1450–1456PubMedCrossRef
65.
Lyssenko V, Nagorny CLF, Erdos MR et al (2009) Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 41:82–88PubMedCrossRef
66.
Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C et al (2009) A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 41:89–94PubMedCrossRef
67.
Rose CS, Ek J, Urhammer SA et al (2005) A –30G>A polymorphism of the beta-cell-specific glucokinase promoter associates with hyperglycemia in the general population of whites. Diabetes 54:3026–3031PubMedCrossRef
68.
Weedon MN, Clark VJ, Qian Y, Ben-Shlomo Y, Timpson N, Ebrahim S et al (2006) A common haplotype of the glucokinase gene alters fasting glucose and birth weight: Association in six studies and population-genetics analyses. Am J Hum Genet 79:991–1001PubMedCrossRef
69.
Sparsø T, Andersen G, Nielsen T, Burgdorf K, Gjesing A, Nielsen A et al (2008) The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia 51:70–75PubMedCrossRef
70.
Orho-Melander M, Melander O, Guiducci C et al (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57:3112–3121PubMedCrossRef
71.
Bouatia-Naji N, Rocheleau G, Van-Lommel L et al (2008) A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 320:1085–1088PubMedCrossRef
72.
Chen WM, Erdos MR, Jackson AU et al (2008) Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest 118:2620–2628PubMed
73.
Hu C, Zhang R, Wang C et al (2009) A genetic variant of G6PC2 is associated with type 2 diabetes and fasting plasma glucose level in the Chinese population. Diabetologia 52:451–456PubMedCrossRef
74.
Andreasen CH, Stender-Petersen KL, Mogensen MS et al (2008) Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes 57:95–101PubMedCrossRef
75.
Ek J, Andersen G, Urhammer SA et al (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma 2 (PPAR-gamma 2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44:1170–1176PubMedCrossRef
76.
Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMedCrossRef
77.
Grunnet LG, Brons C, Jacobsen S et al (2009) Increased recovery rates of phosphocreatine and inorganic phosphate after isometric contraction in oxidative muscle fibers and elevated hepatic insulin resistance in homozygous carriers of the A-allele of FTO rs9939609. J Clin Endocrinol Metab 94:596–602PubMedCrossRef
78.
Sparsø T, Grarup N, Andreasen C et al (2009) Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. Diabetologia 52:1308–1314PubMedCrossRef
79.
Sicree RA, Zimmet PZ, Dunstan DW, Cameron AJ, Welborn TA, Shaw JE (2008) Differences in height explain gender differences in the response to the oral glucose tolerance test—the AusDiab study. Diabet Med 25:296–302PubMedCrossRef
80.
Leger J, Levy-Marchal C, Bloch J et al (1997) Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. BMJ 315:341–347PubMed
81.
Ravelli ACJ, van der Meulen JHP, Michels RPJ et al (1998) Glucose tolerance in adults after prenatal exposure to famine. Lancet 351:173–177PubMedCrossRef
82.
Hales CN, Barker DJ, Clark PM et al (1991) Fetal and infant growth and impaired glucose tolerance at age 64. BMJ 303:1019–1022PubMedCrossRef
83.
Poulsen P, Vaag AA, Kyvik KO, Møller-Jensen D, Beck-Nielsen H (1997) Low birth weight is associated with NIDDM in discordant monozygotic and dizygotic twin pairs. Diabetologia 40:439–446PubMedCrossRef
84.
Jensen CB, Storgaard H, Dela F, Holst JJ, Madsbad S, Vaag AA (2002) Early differential defects of insulin secretion and action in 19-year-old caucasian men who had low birth weight. Diabetes 51:1271–1280PubMedCrossRef
85.
Brøns C, Jensen CB, Storgaard H et al (2008) Mitochondrial function in skeletal muscle is normal and unrelated to insulin action in young men born with low birth weight. J Clin Endocrinol Metab 93:3885–3892PubMedCrossRef
86.
Glümer C, Jørgensen T, Borch-Johnsen K (2003) Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care 26:2335–2340PubMedCrossRef
87.
Dunstan DW, Zimmet PZ, Welborn TA et al (2002) The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25:829–834PubMedCrossRef
88.
Williams JW, Zimmet PZ, Shaw JE et al (2003) Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter? Diabet Med 20:915–920PubMedCrossRef
89.
Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB (1996) Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)—evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425–432PubMedCrossRef
90.
Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef
91.
Tuomilehto J, Lindström J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350PubMedCrossRef
92.
Bloomgarden ZT (2008) American College of Endocrinology Pre-Diabetes Consensus Conference: Part Three. Diabetes Care 31:2404–2409PubMedCrossRef
93.
94.
The International Expert Committee (2009) International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care doi:10.​2337/​dc09-9033
95.
Mooy JM, Grootenhuis PA, de Vries H et al (1996) Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39:298–305PubMedCrossRef
Metadata
Title
Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?
Publication date
01-09-2009
Published in
Diabetologia / Issue 9/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1443-3

Other articles of this Issue 9/2009

Diabetologia 9/2009 Go to the issue

Article

Microarray analysis of genes with impaired insulin regulation in the skeletal muscle of type 2 diabetic patients indicates the involvement of basic helix-loop-helix domain-containing, class B, 2 protein (BHLHB2)

Article

IRS1 G972R polymorphism and type 2 diabetes: a paradigm for the difficult ascertainment of the contribution to disease susceptibility of ‘low-frequency–low-risk’ variants

Short Communication

Insulin-requiring diabetes in rural Ethiopia: should we reopen the case for malnutrition-related diabetes?

Article

Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk

Article

Skeletal myoblast transplantation for attenuation of hyperglycaemia, hyperinsulinaemia and glucose intolerance in a mouse model of type 2 diabetes mellitus

Article

Continuous low- to moderate-intensity exercise training is as effective as moderate- to high-intensity exercise training at lowering blood HbA1c in obese type 2 diabetes patients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits